SPSpruce Biosciences, Inc. SPRB · NASDAQ
$39.65 -4.39% (-$1.82)
- Market cap
- $114.1M
- Enterprise value
- $25.5M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- -50.5%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- 3.30
- Free float
- 70.2%
About the company
Spruce Biosciences, Inc. (SPRC) is a biotechnology company focused on developing innovative therapeutics for serious endocrine disorders. Their research primarily targets diseases that impact the adrenal glands and hormonal imbalances. The company aims to develop effective and safe therapies to help patients improve their quality of life and manage their health conditions. Spruce Biosciences invests in clinical trials and research to bring new and promising solutions to the field of endocrinology. For investors seeking potential growth opportunities in the biotechnology sector, Spruce Biosciences, Inc. (SPRC) may present an intriguing choice.
Sector
Healthcare
Industry
Biotechnology
CEO
Javier Szwarcberg
Employees
22
Headquarters
South San Francisco
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
Financial health
Can it carry its debt?
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number